Molecular Imaging Market Forecast 2026-2036: Market to Reach USD 12,598.9 Million by 2036 at 7.5% CAGR

NEWARK, DE | The molecular imaging market stood at USD 5,686.4 million in 2025 and is projected to expand significantly, reaching USD 6,112.9 million in 2026 before climbing to USD 12,598.9 million by 2036. Future Market Insights forecasts a steady CAGR of 7.5% over the forecast period. This expansion reflects the market's critical role in advancing precision diagnostics and therapeutics, particularly through the integration of imaging with targeted therapies in oncology, neurology, and theranostics applications.

Read Full Report:https://www.futuremarketinsights.com/reports/molecular-imaging-market

Market snapshot: global market 2026 - 2036

Market size in 2026? USD 6,112.9 million
Market size in 2036? USD 12,598.9 million
CAGR? 7.5%
Leading modality segment(s) and shares: PET/CT holds the largest installed base share; PET/MRI is the fastest-growing premium segment
Leading application: Oncology accounts for the majority of molecular imaging procedures globally
Key growth regions: Asia Pacific is the fastest-growing region, with India (9.2% CAGR) and China (8.8% CAGR) leading due to expanding nuclear medicine departments and PET/CT installations
Top companies: GE Healthcare (17.0%), Siemens Healthineers (9.5%), Philips Healthcare (10.0%), Bruker Corporation (2.3%), and others including Fujifilm Holdings Corporation, Toshiba Medical System Corp., Hitachi Medical Corp., among combined players

Market Momentum (YoY Path)

The molecular imaging market demonstrates consistent upward momentum, with values rising from USD 5,686.4 million in 2025 to USD 6,112.9 million in 2026. Growth continues steadily, supported by expanding installations and radiopharmaceutical advancements. By 2028 and 2030, the trajectory builds on oncology and neurology demand, while 2031 and 2033 mark accelerated adoption of theranostics and total-body PET systems. The market reaches USD 12,598.9 million by 2036, delivering an absolute dollar growth of USD 6,486.0 million over the decade and establishing molecular imaging as a high-growth area in diagnostic capital equipment and radiopharmaceuticals.

Why the Market is Growing

The molecular imaging market is propelled by converging forces that enhance both diagnostic and therapeutic capabilities. Theranostic agent approvals, such as Lu-177 PSMA and Lu-177 DOTATATE, transform diagnostic imaging into revenue-generating therapeutic platforms. Total-body PET scanner installations reduce scan times, boost clinical throughput, and support research. Alzheimer diagnostic imaging using amyloid and tau PET addresses the expanding neurology indication amid aging populations. Investments in radiopharmaceutical supply chains, particularly for Lutetium-177 and Actinium-225, enable scalable delivery of radioligand therapies, while the shift toward personalized medicine and chronic disease management further fuels demand for precise molecular-level visualization.

Segment Spotlight

Modality PET/CT maintains the largest installed base share in molecular imaging, benefiting from its established role in oncology, cardiology, and neurology. PET/MRI emerges as the fastest-growing premium segment, driven by enhanced diagnostic precision through fusion of functional and anatomical data. Hybrid systems support advanced applications in theranostics and drug research, with AI integration and detector advancements accelerating adoption.

Application Oncology dominates molecular imaging procedures globally, fueled by rising cancer prevalence and the push for early diagnosis, tumor staging, treatment planning, and response assessment. PET, SPECT, and hybrid systems, combined with targeted radiotracers and theranostic strategies, enable precision medicine in cancer care. Neurology gains momentum as an emerging high-growth area, with amyloid and tau PET aiding early detection of neurodegenerative diseases like Alzheimer's, supported by new tracers and AI-driven analysis.

End Use Hospitals lead as primary end users, leveraging molecular imaging for clinical diagnostics and therapeutic planning in oncology, cardiology, and neurology. Diagnostic imaging centers and ambulatory surgical centers contribute through specialized procedures, while research applications in pharmaceutical trials expand usage.

Drivers, Opportunities, Trends, Challenges

Drivers Theranostics bridges diagnosis and therapy using shared molecular targets, with agent approvals creating new revenue streams. Total-body PET and hybrid systems improve efficiency, while amyloid/tau imaging addresses neurology needs in aging demographics. Radiopharmaceutical investments ensure supply for clinical-scale therapies.

Opportunities Personalized medicine drives customized imaging agents for better specificity. AI and machine learning enhance image analysis, workflow, and accuracy. Chronic disease growth demands advanced early diagnostics. Partnerships across pharma, research, and device sectors foster innovative probes, with emerging markets offering affordable solutions.

Trends Hybrid devices like PET/MRI and PET/CT advance early disease detection. Targeted agents improve oncology, cardiology, and neurology outcomes. Theranostics combines imaging and therapy, while AI boosts analysis and portable devices increase accessibility. Sustainability efforts focus on eco-friendly tracers and waste reduction.

Challenges Product recalls and safety concerns from adverse events slow progress. Stringent FDA and EMA regulations delay approvals and launches. High device and procedure costs limit access, particularly in underserved areas.

Country Growth Outlook (CAGR)

China: 8.8%
India: 9.2%
Germany: 6.8%
France: 6.5%
UK: Not specified in detail, but contributes via university centers and theranostics
USA: 7.2%
Brazil: 6.5%

Competitive Landscape

The molecular imaging market features strong competition among leading players investing in next-generation technologies, regulatory approvals, and alliances. GE Healthcare holds the top position with 17.0% share through its PET, SPECT, and AI-integrated hybrid solutions. Siemens Healthineers (9.5%) focuses on high-performance systems for oncology and theranostics, Philips Healthcare (10.0%) on AI-driven analytics, and Bruker Corporation (2.3%) on preclinical imaging. Other contributors include Fujifilm Holdings Corporation, Toshiba Medical System Corp., Hitachi Medical Corp., and more, driving innovation and diversity.

Subscribe for Year-Round Insights → Stay ahead with quarterly and annual data updates: https://www.futuremarketinsights.com/reports/brochure/rep-gb-724

Get Access of Report Sample:https://www.futuremarketinsights.com/reports/sample/rep-gb-724

Scope of the Report

Quantitative Units: USD 6,112.9 million (2026) to USD 12,598.9 million (2036), at a CAGR of 7.5%
Key Segments: Modality (PET, PET-CT, PET-MR, SPECT, Software, Magnetic resonance spectroscopy, Molecular ultrasound imaging); Application (Cardiology, Oncology, Gastrointestinal disorders, Neurological disorders, Others); End User (Hospitals, Ambulatory surgical centers, Diagnostics imaging centers); Region (North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe, Middle East & Africa)
Countries Covered: Includes detailed insights on USA, Germany, India, China, Brazil, France, UK, and broader regions
Key Companies Profiled: Siemens Healthineers, GE HealthCare, Philips, Lantheus Holdings, Cardinal Health, Bracco Imaging, Bruker Corporation, United Imaging Healthcare, Eczacibasi-Monrol, Bayer Radiopharmaceuticals, Fujifilm Holdings Corporation, and others

FAQ

What is the molecular imaging market size in 2026? The molecular imaging market is estimated at USD 6,112.9 million in 2026.

What is the projected market size by 2036? The market is forecasted to reach USD 12,598.9 million by 2036.

What is the CAGR for the forecast period? FMI projects a 7.5% CAGR from 2026 to 2036.

Which modality leads the market? PET/CT holds the largest installed base share, while PET/MRI grows fastest as a premium segment.

Which application dominates procedures? Oncology accounts for the majority of molecular imaging procedures globally.

Which regions show the strongest growth? Asia Pacific leads growth, with India at 9.2% CAGR and China at 8.8% CAGR, driven by infrastructure expansion.

Explore More Related Studies Published by FMI Research:

Digital Colony Counter Market: https://www.futuremarketinsights.com/reports/digital-colony-counter-market

Baby Breathing Monitor Market: https://www.futuremarketinsights.com/reports/baby-breathing-monitor-market

Gastrointestinal Therapeutics Market: https://www.futuremarketinsights.com/reports/gastrointestinal-therapeutics-market

Preterm Birth Prevention and Management Market: https://www.futuremarketinsights.com/reports/preterm-birth-prevention-and-management-market

Infant Gut Health Market: https://www.futuremarketinsights.com/reports/infant-gut-health-market

Why FMI: Decisions that Change Outcomes- https://www.futuremarketinsights.com/why-fmi

Have a specific Requirements and Need Assistant on Report Pricing or Limited Budget please contact us - sales@futuremarketinsights.com

Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

About Future Market Insights (FMI)

Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization, trusted by Fortune 500 clients and global enterprises. With operations in the U.S., UK, India, and Dubai, FMI provides data-backed insights and strategic intelligence across 30+ industries and 1200 markets worldwide.

This release was published on openPR.